Decision to widen access to nivolumab and ipilimumab for resectable melanoma

We are pleased to announce our decision to widen access to nivolumab and ipilimumab for treatment of resectable melanoma.

From 1 May 2026, nivolumab in combination with ipilimumab will be funded for people with stage 3B to stage 4 melanoma that can be removed with surgery.

This decision was informed by consultation feedback from people with melanoma, their whānau, advocacy groups, clinicians and other health sector stakeholders.

You can read the full decision here: Decision to widen access to nivolumab and ipilimumab for resectable melanoma

Ngā mihi nui,

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz